TLDR Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
This narrative review discusses the potential of biologics and small molecule targeted therapies in treating pediatric alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa in the US. The success of ongoing clinical trials could result in these therapies being included in treatment guidelines, offering new opportunities for effective disease management. These therapies enable personalized therapeutic interventions, which could significantly improve health outcomes for children suffering from these chronic skin conditions.
January 2024 in “Journal der Deutschen Dermatologischen Gesellschaft” Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.
84 citations
,
August 2023 in “Drugs”
3 citations
,
August 2023 in “Pediatric dermatology” Antibiotics and finasteride are very effective for treating pediatric hidradenitis suppurativa.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
17 citations
,
January 2022 in “Annals of Dermatology” Severe pediatric alopecia areata worsens quality of life for patients and families.
48 citations
,
April 2021 in “Journal of the American Academy of Dermatology” Topical corticosteroids are the best initial treatment for children's alopecia areata.
44 citations
,
April 2019 in “Journal of the American Academy of Dermatology” Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.
April 2019 in “International journal of research in dermatology” A child with rough nails also had hair loss and allergies.